Sanochemia Pharmazeutika AG
- ISIN AT0000776307
- Country Austria
Company profile
SANOCHEMIA, the Specialty Pharma Company, is an internationally active player with a long-standing tradition in the development and manufacture of active pharmaceutical ingredients and drugs. The Company specialises in segments of the oncology, pain management, neurodegeneration and, in particular, imaging diagnostic markets. Significant progress has already been made in the global marketing of the Company’s radiological products. In the area of R&D, the focus is on the development of products to extend its in-house portfolio. Through the acquisition of Alvetra und Werfft GmbH, SANOCHEMIA has succeeded in consolidating its standing in the area of veterinary medicine and also acquired additional subsidiaries in promising markets.
• As a fully integrated pharmaceutical company, SANOCHEMIA covers all of the key links in the value-added chain – from the development and production of active pharmaceutical ingredients to the manufacture, marketing and sale of drugs and diagnostics. This full integration has been furthered by the expansion of sterile production facilities and the logistics centre at its Neufeld site.
• The focus here lies on fast-growing pharmaceutical markets and segments with high levels of demand for new diagnostics and therapeutics. Given its extensive network of subsidiaries and marketing partnerships, SANOCHEMIA is already well established and increasingly successful in expanding its activities in up-and-coming global pharmaceutical markets. The focus in the past financial year lay on markets in Asia and the Middle East.
• SANOCHEMIA has an established portfolio of human and veterinarian drugs and is continuously forging ahead with research and development work based on this portfolio. The core focus is currently on the development of efficient cancer diagnostics such as Vidon®, for use in the photodynamic diagnosis of bladder carcinomas, and Secrelux®, a pancreatic function diagnostic. The most advanced product candidate at present is Cyclolux®, a next generation imaging agent for magnetic resonance tomography.
• As a fully integrated pharmaceutical company, SANOCHEMIA covers all of the key links in the value-added chain – from the development and production of active pharmaceutical ingredients to the manufacture, marketing and sale of drugs and diagnostics. This full integration has been furthered by the expansion of sterile production facilities and the logistics centre at its Neufeld site.
• The focus here lies on fast-growing pharmaceutical markets and segments with high levels of demand for new diagnostics and therapeutics. Given its extensive network of subsidiaries and marketing partnerships, SANOCHEMIA is already well established and increasingly successful in expanding its activities in up-and-coming global pharmaceutical markets. The focus in the past financial year lay on markets in Asia and the Middle East.
• SANOCHEMIA has an established portfolio of human and veterinarian drugs and is continuously forging ahead with research and development work based on this portfolio. The core focus is currently on the development of efficient cancer diagnostics such as Vidon®, for use in the photodynamic diagnosis of bladder carcinomas, and Secrelux®, a pancreatic function diagnostic. The most advanced product candidate at present is Cyclolux®, a next generation imaging agent for magnetic resonance tomography.